IN2012DN03043A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03043A IN2012DN03043A IN3043DEN2012A IN2012DN03043A IN 2012DN03043 A IN2012DN03043 A IN 2012DN03043A IN 3043DEN2012 A IN3043DEN2012 A IN 3043DEN2012A IN 2012DN03043 A IN2012DN03043 A IN 2012DN03043A
- Authority
- IN
- India
- Prior art keywords
- present
- bace1
- oxazin
- difluoro
- alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09178983 | 2009-12-11 | ||
PCT/EP2010/068912 WO2011069934A1 (en) | 2009-12-11 | 2010-12-06 | 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03043A true IN2012DN03043A (zh) | 2015-07-31 |
Family
ID=43585547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3043DEN2012 IN2012DN03043A (zh) | 2009-12-11 | 2010-12-06 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8389513B2 (zh) |
EP (1) | EP2509965A1 (zh) |
JP (1) | JP5584778B2 (zh) |
KR (1) | KR101506773B1 (zh) |
CN (1) | CN102712609A (zh) |
AR (1) | AR079327A1 (zh) |
AU (1) | AU2010330031B2 (zh) |
BR (1) | BR112012013175A2 (zh) |
CA (1) | CA2776727C (zh) |
CL (1) | CL2012001464A1 (zh) |
CO (1) | CO6541656A2 (zh) |
CR (1) | CR20120262A (zh) |
EC (1) | ECSP12011961A (zh) |
IL (1) | IL219107A (zh) |
IN (1) | IN2012DN03043A (zh) |
MA (1) | MA34779B1 (zh) |
MX (1) | MX2012006493A (zh) |
MY (1) | MY169962A (zh) |
NZ (1) | NZ599008A (zh) |
PE (1) | PE20121500A1 (zh) |
RU (1) | RU2515221C2 (zh) |
SG (1) | SG181610A1 (zh) |
TW (1) | TWI487704B (zh) |
UA (1) | UA103272C2 (zh) |
WO (1) | WO2011069934A1 (zh) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103936690B (zh) | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
CA2683887A1 (en) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein |
EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
ES2738123T3 (es) | 2008-06-13 | 2020-01-20 | Shionogi & Co | Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa |
US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
MX2012006491A (es) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
CN102933564B (zh) | 2010-06-09 | 2015-07-22 | 詹森药业有限公司 | 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物 |
AU2011321427A1 (en) | 2010-10-29 | 2013-05-02 | Shionogi & Co., Ltd. | Naphthyridine derivative |
EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
EP2643325A1 (en) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
BR112013015430A2 (pt) | 2010-12-22 | 2016-09-20 | Janssen Pharmaceutica Nv | derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace) |
US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
AP3807A (en) | 2011-01-13 | 2016-09-30 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
TWI547482B (zh) * | 2011-01-25 | 2016-09-01 | 陶氏農業科學公司 | 增加可回收之3-氯-4,5,6-三氟-2-氰吡啶之量的改良方法 |
US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US8815841B2 (en) * | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
ES2534973T3 (es) | 2011-03-09 | 2015-04-30 | Janssen Pharmaceutica N.V. | Derivados de 3,4-dihidro-pirrolo[1,2-a]pirazin-1-ilamina útiles como inhibidores de beta-secretasa (BACE) |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
JP2014514302A (ja) | 2011-04-13 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | Bace阻害薬としての5−置換されたイミノチアジン類およびそれのモノおよびジオキシド、組成物およびそれらの使用 |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US8785436B2 (en) * | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
US9079919B2 (en) * | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
BR112013031510A2 (pt) * | 2011-06-07 | 2016-12-27 | Hoffmann La Roche | [1,3]oxazinas |
US8987255B2 (en) * | 2011-06-07 | 2015-03-24 | Hoffmann-La Roche Inc. | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
US8476264B2 (en) * | 2011-09-21 | 2013-07-02 | Hoffmann-La Roche Inc. | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors |
UA111749C2 (uk) * | 2011-12-05 | 2016-06-10 | Янссен Фармацевтика Нв | Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну |
PE20142376A1 (es) * | 2012-01-26 | 2015-01-17 | Hoffmann La Roche | Fluormetil-5,6-dihidro-4h-[1,3]oxazinas |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
JP2015514073A (ja) | 2012-03-20 | 2015-05-18 | エラン ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニー | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンbace阻害剤、ならびにその組成物および使用 |
CN104334554B (zh) * | 2012-05-24 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的5‑氨基[1,4]噻嗪类 |
WO2014001228A1 (en) * | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
WO2014059185A1 (en) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
WO2014065434A1 (en) * | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
WO2014120658A1 (en) | 2013-01-29 | 2014-08-07 | Amgen Inc. | Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors |
EP2961749B1 (en) * | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
CN105164121A (zh) | 2013-03-08 | 2015-12-16 | 美国安进公司 | 作为β分泌酶抑制剂的全氟化环丙基稠合的1,3-噁嗪-2-胺化合物以及其使用方法 |
BR112015019412A8 (pt) | 2013-04-11 | 2019-11-12 | Hoffmann La Roche | inibidores de bace1, seus usos, e composição farmacêutica |
AU2014257594A1 (en) * | 2013-04-26 | 2015-10-08 | F. Hoffmann-La Roche Ag | Synthesis of BACE inhibitors |
JP6387402B2 (ja) | 2013-06-12 | 2018-09-05 | ヤンセン ファーマシューティカ エヌ.ベー. | β−セクレターゼ(BACE)の阻害剤としての4−アミノ−6−フェニル−5,6−ジヒドロイミダゾ[1,5−A]ピラジン−3(2H)−オン誘導体 |
ES2721073T3 (es) | 2013-06-12 | 2019-07-26 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE) |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
WO2015017407A1 (en) | 2013-07-30 | 2015-02-05 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
WO2016096979A1 (en) | 2014-12-18 | 2016-06-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase |
PE20171349A1 (es) | 2015-03-20 | 2017-09-13 | Hoffmann La Roche | Inhibidores de bace1 |
US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
ES2910367T3 (es) | 2016-12-15 | 2022-05-12 | Amgen Inc | Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso |
WO2018112094A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
MA52722A (fr) | 2016-12-15 | 2021-04-14 | Amgen Inc | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
EP3555085B1 (en) | 2016-12-15 | 2020-12-02 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
MX2019007102A (es) | 2016-12-15 | 2019-12-16 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
AU2019258575A1 (en) | 2018-04-27 | 2020-10-29 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
CN110747276B (zh) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Bace2作为胶质瘤预后/诊断/治疗标志物的应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2360258A1 (en) * | 1999-02-09 | 2000-08-17 | Timothy L. Macdonald | Felbamate derived compounds |
US7566730B2 (en) * | 2002-09-10 | 2009-07-28 | Elan Pharmaceuticals, Inc. | Substituted aminoethers for the treatment of Alzheimer's disease |
CA2505098A1 (en) * | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
KR20060066057A (ko) * | 2003-06-30 | 2006-06-15 | 다이이찌 세이야꾸 가부시기가이샤 | 복소환 메틸 설폰 유도체 |
EP1794145A1 (en) | 2004-09-20 | 2007-06-13 | Biolipox AB | Pyrazole compounds useful in the treatment of inflammation |
WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
CN103936690B (zh) | 2005-10-25 | 2016-06-08 | 盐野义制药株式会社 | 氨基二氢噻嗪衍生物 |
SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
CA2683887A1 (en) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein |
UA101352C2 (uk) | 2008-01-18 | 2013-03-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Конденсоване похідне амінодигідротіазину |
JP5258904B2 (ja) | 2008-02-18 | 2013-08-07 | エフ.ホフマン−ラ ロシュ アーゲー | 4,5−ジヒドロオキサゾール−2−イルアミン誘導体 |
GB0912778D0 (en) * | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
EP2511269A4 (en) * | 2009-12-11 | 2013-04-24 | Shionogi & Co | FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP |
-
2010
- 2010-06-12 UA UAA201208098A patent/UA103272C2/uk unknown
- 2010-12-03 US US12/959,412 patent/US8389513B2/en not_active Expired - Fee Related
- 2010-12-06 MA MA34922A patent/MA34779B1/fr unknown
- 2010-12-06 NZ NZ599008A patent/NZ599008A/xx not_active IP Right Cessation
- 2010-12-06 JP JP2012542481A patent/JP5584778B2/ja not_active Expired - Fee Related
- 2010-12-06 SG SG2012042560A patent/SG181610A1/en unknown
- 2010-12-06 EP EP10785437A patent/EP2509965A1/en not_active Withdrawn
- 2010-12-06 PE PE2012000803A patent/PE20121500A1/es not_active Application Discontinuation
- 2010-12-06 AU AU2010330031A patent/AU2010330031B2/en not_active Ceased
- 2010-12-06 MY MYPI2012002594A patent/MY169962A/en unknown
- 2010-12-06 WO PCT/EP2010/068912 patent/WO2011069934A1/en active Application Filing
- 2010-12-06 KR KR1020127017919A patent/KR101506773B1/ko not_active IP Right Cessation
- 2010-12-06 MX MX2012006493A patent/MX2012006493A/es active IP Right Grant
- 2010-12-06 BR BR112012013175A patent/BR112012013175A2/pt not_active IP Right Cessation
- 2010-12-06 RU RU2012126989/04A patent/RU2515221C2/ru not_active IP Right Cessation
- 2010-12-06 CA CA2776727A patent/CA2776727C/en not_active Expired - Fee Related
- 2010-12-06 CN CN2010800561519A patent/CN102712609A/zh active Pending
- 2010-12-06 IN IN3043DEN2012 patent/IN2012DN03043A/en unknown
- 2010-12-08 TW TW099142877A patent/TWI487704B/zh not_active IP Right Cessation
- 2010-12-09 AR ARP100104535A patent/AR079327A1/es unknown
-
2012
- 2012-04-05 IL IL219107A patent/IL219107A/en not_active IP Right Cessation
- 2012-05-21 CR CR20120262A patent/CR20120262A/es unknown
- 2012-06-05 CL CL2012001464A patent/CL2012001464A1/es unknown
- 2012-06-08 EC ECSP12011961 patent/ECSP12011961A/es unknown
- 2012-07-06 CO CO12113850A patent/CO6541656A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120104598A (ko) | 2012-09-21 |
BR112012013175A2 (pt) | 2019-09-24 |
CA2776727C (en) | 2016-05-31 |
AU2010330031A1 (en) | 2012-06-07 |
JP2013513563A (ja) | 2013-04-22 |
CL2012001464A1 (es) | 2014-03-07 |
CR20120262A (es) | 2012-07-27 |
SG181610A1 (en) | 2012-07-30 |
CO6541656A2 (es) | 2012-10-16 |
AR079327A1 (es) | 2012-01-18 |
CA2776727A1 (en) | 2011-06-16 |
IL219107A0 (en) | 2012-06-28 |
JP5584778B2 (ja) | 2014-09-03 |
RU2515221C2 (ru) | 2014-05-10 |
MA34779B1 (fr) | 2014-01-02 |
AU2010330031B2 (en) | 2013-06-20 |
PE20121500A1 (es) | 2012-11-05 |
US20110144097A1 (en) | 2011-06-16 |
KR101506773B1 (ko) | 2015-03-27 |
CN102712609A (zh) | 2012-10-03 |
NZ599008A (en) | 2013-08-30 |
UA103272C2 (uk) | 2013-09-25 |
MY169962A (en) | 2019-06-19 |
MX2012006493A (es) | 2012-07-03 |
EP2509965A1 (en) | 2012-10-17 |
IL219107A (en) | 2015-10-29 |
TW201124408A (en) | 2011-07-16 |
ECSP12011961A (es) | 2012-07-31 |
US8389513B2 (en) | 2013-03-05 |
WO2011069934A1 (en) | 2011-06-16 |
TWI487704B (zh) | 2015-06-11 |
RU2012126989A (ru) | 2014-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03043A (zh) | ||
IN2012DN00766A (zh) | ||
MX2013010795A (es) | 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2). | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
WO2012104263A3 (en) | 1,4 oxazines as bace1 and/or bace2 inhibitors | |
MX2013014007A (es) | [1,3] oxazinas. | |
MX2013008478A (es) | 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2). | |
MX2013013692A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2). | |
MX2013008213A (es) | N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
PH12014501334A1 (en) | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines | |
MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
NZ596579A (en) | Bace inhibitors | |
IN2012DN01233A (zh) | ||
MX2009007411A (es) | Derivados de espiropiperidina-glicinamida. | |
PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
MX2013002398A (es) | Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes. | |
EP2073635A4 (en) | MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER |